Azitra shares are trading lower after the company announced a 1-for-30 reverse stock split.
$AZTR
Biotechnology: Pharmaceutical Preparations
Health Care
Azitra shares are trading lower after the company announced a 1-for-30 reverse stock split.
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
DEFA14A - Azitra, Inc. (0001701478) (Filer)
8-K - Azitra, Inc. (0001701478) (Filer)
S-8 - Azitra, Inc. (0001701478) (Filer)
MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestonesBRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484). ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash.
BRANFORD, Conn., Feb. 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome; ATR-04, being developed in a Phase 1/2 trial for the treatment of moderate to severe EG
BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its Special Meeting scheduled for and convened on February 6, 2026, (the "Special Meeting") has been adjourned until March 6, 2026, at 11:00 a.m. Eastern Time (the "Reconvened Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the U.S. Securities and Exchange Commission (the "SEC") on January 2, 2026 (the "Special Meeting Proxy Statement") becau
4 - Azitra, Inc. (0001701478) (Issuer)
4 - Azitra, Inc. (0001701478) (Issuer)
4 - Azitra, Inc. (0001701478) (Issuer)
4 - Azitra, Inc. (0001701478) (Issuer)
BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will
SC 13G/A - Azitra, Inc. (0001701478) (Subject)
SC 13G/A - Azitra, Inc. (0001701478) (Subject)
SC 13G/A - Azitra, Inc. (0001701478) (Subject)
BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu
BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat
Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres